Interview with Amit Mehta, Managing Director, S. Amit & Co
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Address: 101-A Neelam Centre, 249-B Hind Cycle Road, Worli, Mumbai 400 030, India
Tel: +91 22 4001 3000
S. Amit Speciality Chemicals Pvt. Ltd. is a leading full-service Chemistry Solutions provider in India delivering products and services in the areas of speciality chemicals, intermediates and performance chemicals for diverse applications including pharmaceuticals, agrochemicals, polymers & plastics, and paints and coating.
Over the last six decades, the Company has transitioned from representing international laboratory chemical suppliers to marketing 1 or 2 steps of chemistries to supplying advanced intermediates and performance chemicals such as reducing agents, resolving agents, encapsulated catalysts, etc. Focussed on its broad-based relationships with both customers and suppliers, the objective has always been to add value to the chemical supply chain for both parties.
Today, as an integrated solutions provider, the S. Amit Group of Companies focuses on offering a full range of supply chain services including – representation of manufacturers, global and local sourcing, distribution, virtual manufacturing, and identifying problems and recommending innovative chemical solutions. This allows our customers and suppliers to effectively extract value from the supply chain based on their needs and the market situation.
In January 2011, S. Amit acquired Reaxa U.K., a company actively involved in developing and supplying encapsulated metal catalysts for synthetic organic chemistry.
Through its various group companies, the S. Amit Group provides
Indenting
Local Sales and Distribution
Exports
Virtual Manufacturing Services
Products and services are branded through the following group companies – S. Amit, Finorga,
Chem Amit, Perfo Chem and Brom Chem
The S. Amit Group also has a joint venture company, Diamines & Chemicals Ltd. that manufactures piperazine at its plant in Baroda, Gujarat.
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation.…
Under the leadership of Ajay Tandon and the foundational work of Dr Kiran Marthak, Indian firm Veeda Clinical Research has strategically expanded its capabilities and global footprint. The company has…
Sampada Gosavi explains how she has led a transformation of Astellas’ operations in India to launch innovative products in oncology and women’s health, coupled with a commitment to building internal…
Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines…
Terumo India’s Shishir Agarwal outlines the company’s strategic roadmap and growth trajectory in India, highlighting the organization’s focus on understanding the healthcare landscape, enhancing organizational capabilities, and diversifying the product…
The State of Gujarat is one of India’s most culturally diverse, the birthplace of ‘Father of the Nation’ Mahatma Gandhi, and the only place in the world where Asiatic lions…
Mohal Sarabhai, managing director of Ambalal Sarabhai Enterprises Limited (ASE) on transforming his family’s failing century-old business and creating new companies beneath the ASE Holdings umbrella, including a joint venture…
Dr Basant Garg explains the role and impact of the National Health Authority (NHA) in India, including its pivotal role in executing the Ayushman Bharat universal health coverage initiative. Dr…
Dr Arunish Chawla details the policy strategies underlying the explosive prospected growth of India’s pharmaceutical sector to USD 120-150 billion by 2030, including rigorous adherence to international quality standards. Highlighting…
At a transformational moment for Indian pharma, OPPI’s Anil Matai outlines how the country’s government is more receptive to innovation and action-oriented than ever before, how the industry is increasingly…
Solid dosage forms like capsules and tablets make up over 70 percent of all medicines prescribed globally. In the view of Ajit Singh, chairman of Indian solid dosage form pioneer…
Pharmexcil’s Ravi Uday Bhaskar discusses how Indian pharma is rebuilding global confidence in its exports via a focus on quality, expanding into high-potential new markets like those in Latin America,…
See our Cookie Privacy Policy Here